GleamWall
中文EN

SANA Sana Biotechnology, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1770121 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY36.3%
TTM EPS YoY45.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-79.5%
ROA-36.8%
ROIC (approx.)-109.1%
Asset turnover—

Leverage & solvency

Liabilities / assets52.0%
Debt / equity0.00x
Current ratio1.77x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.95x
Accruals ratio-1.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$33.93M$30.73M$28.72M$34.92M$30.11M$29.76M$37.19M$47.04M
SG&A expense$10.94M$10.78M$11.46M$12.19M$10.29M$10.34M$11.48M$17.28M
Operating income$18.51M-$65.42M-$48.61M-$61.20M-$43.52M-$94.97M-$50.63M-$50.87M
Net income$20.40M-$63.63M-$47.21M-$58.83M-$42.15M-$93.80M-$49.39M-$49.07M
EBITDA$21.51M-$63.22M-$46.22M-$58.10M-$40.31M-$92.08M-$46.98M-$45.16M
EPS (basic)0.07-0.22-0.17—-0.16-0.39-0.21—
EPS (diluted)0.07-0.22-0.17—-0.16-0.39-0.21—
Weighted avg. shares (diluted)308.79M295.67M276.86M—260.49M238.41M237.58M—
Balance sheet
Cash & equivalents$41.10M$57.07M$83.80M$71.87M$107.55M$75.47M$100.33M$131.40M
Short-term investments$80.62M$103.42M$17.34M$66.51M$49.70M$1.40M$8.57M$24.93M
Current assets$132.31M$170.63M$111.69M$148.68M$161.76M$82.50M$112.73M$160.81M
PP&E, net$23.11M$25.16M$25.67M$26.91M$29.93M$33.08M$73.69M$77.31M
Goodwill$140.63M$140.63M$140.63M$140.63M$140.63M$140.63M$140.63M$140.63M
Intangibles$59.20M$59.20M$59.20M$59.20M$59.20M$59.20M$59.20M$59.20M
Total assets$376.13M$431.52M$373.59M$416.89M$435.43M$361.64M$445.47M$501.02M
Current liabilities$74.88M$123.75M$86.27M$78.73M$35.51M$33.44M$33.16M$45.43M
Total liabilities$195.76M$276.95M$254.35M$256.01M$240.12M$239.09M$236.39M$250.52M
Shareholders' equity$180.36M$154.57M$119.24M$160.88M$195.31M$122.56M$209.08M$250.50M
Shares outstanding299.52M299.31M269.82M266.73M262.26M230.51M225.46M223.92M
Cash flow statement
Operating cash flow-$38.75M-$32.79M-$37.38M-$32.64M-$29.43M-$33.10M-$48.66M-$47.16M
Capital expenditure$791,000$1.62M$288,000$873,000$41,000-$112,000$136,000$436,000
Free cash flow-$39.54M-$34.41M-$37.67M-$33.51M-$29.47M-$32.99M-$48.79M-$47.60M
Investing cash flow$22.35M-$87.52M$49.44M-$16.50M-$48.02M$7.68M$16.60M$47.09M
Financing cash flow$0$93.58M-$128,000$17.65M$109.54M$561,000$982,000$643,000
Depreciation & amortization$3.00M$2.20M$2.39M$3.10M$3.20M$2.90M$3.65M$5.70M
Stock-based compensation$5.33M$5.34M$5.66M$6.34M$5.48M$6.63M$7.02M$6.44M

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.